Abacavir sulfate (DrugBank: Abacavir, Sulfate)
3 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
135 | アイカルディ症候群 | 0 |
265 | 脂肪萎縮症 | 3 |
325 | 遺伝性自己炎症疾患 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00028314 (ClinicalTrials.gov) | March 2002 | 20/12/2001 | Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients | A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting | HIV Infections;Lipodystrophy;Wasting Disease | Drug: Abacavir sulfate;Drug: Atazanavir/Ritonavir;Drug: Lopinavir/Ritonavir;Drug: Nevirapine | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 13 Years | N/A | Both | 150 | N/A | United States |
2 | NCT00021463 (ClinicalTrials.gov) | April 2001 | 14/7/2001 | Changing to Nonprotease Inhibitor Treatment to Improve Side Effects | Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities | HIV Infections;Lipodystrophy | Drug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: Nevirapine | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 13 Years | N/A | Both | 342 | Phase 2 | United States |
3 | NCT00005764 (ClinicalTrials.gov) | May 2000 | 30/5/2000 | A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients | Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) | HIV Infections;Lipodystrophy | Drug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: Lamivudine | Glaxo Wellcome | NULL | Completed | 18 Years | N/A | Both | 100 | Phase 4 | United States |